Slide 1: Conference call presentation 9M 2022/23
Conference call presentation 9M 2022/23 Morten, Denmark Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Continued solid performance in Q3 2022/23
NEW IMAGE Continued solid performance in Q3 2022/23 Update picture Organic Reported ROIC growth EBIT margin 8% 28% * * 19% ** *before special items **after tax and before special items 3 Morten | Denmark
Slide 4: Organic growth of 8% in 9M 2022/23 with continued good momentum across business areas and geographies
Organic growth of 8% in 9M 2022/23 with continued good momentum across business areas and geographies 9M 2022/23 revenue by business area 9M 2022/23 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm gr
Slide 5: 9M reported growth was up 11%, with ~4%-points contribution from the Atos Medical acquisition
9M reported growth was up 11%, with ~4%-points contribution from the Atos Medical acquisition and ~1%-point headwind from currencies 9M 2022/23 Revenue development (DKKm) 9M 2022/23 highlights • Organic growth was 8% or DKK 1,248 million, driven by: 1,754m DKK • Solid growth in Chronic Care across r
Slide 6: Reported EBIT margin of 28% in 9M, reflecting impact from cost inflation
Reported EBIT margin of 28%1 in 9M, reflecting impact from cost inflation, increased level of commercial activity and amortisation costs 9M 2022/23 EBIT margin development before special items (%) 9M 2022/23 highlights • Gross margin was 67%, against 69% in 9M last year 30.8 -2.0 • Negative impact f
Slide 7: Adj. FCF in 9M was DKK 2,167 million
Adj. FCF in 9M was DKK 2,167 million. Operating cash flow impacted by increased working capital; NWC-to-sales now expected at 25% for FY FCF development1 FCF development Comments 9M 2022/23 highlights • Free cash flow for 9M 2022/23 was an inflow of DKK 1,690 million compared to an outflow of DKK 8,
Slide 8: Unchanged organic growth and EBIT margin guidance for FY 22/23
Unchanged organic growth and EBIT margin* guidance for FY 2022/23 Organic revenue growth Around 8% Reported revenue growth in DKK 8-9% Reported EBIT margin* 28-29% Effective tax rate Around 21% Capital expenditures Around 1.3 bn DKK *before special items 8
Slide 9: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding